EUVIMEDEUVIMED entdecken
Crossref

Decision and timing of safety‐related labeling changes for new drugs in Japan: Comparison with the United States and the European Union

Koichi Fukuda iD, Mamoru Narukawa

Pharmacoepidemiology and Drug Safety · 2023

DOI: 10.1002/pds.5664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Koichi Fukuda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Japan. Hauptthemen laut MEDLINE: Drug Approval, Pharmacovigilance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to compare safety‐related labeling changes for newly approved drugs in Japan with those in the United States (US) and the European Union (EU), where guidance on the details of pharmacovigilance (PV) process has been published, to examine the extent to which the Japanese PV process is working.

Methods

Safety‐related labeling changes for new drugs approved within 1 year in Japan, the US, and the EU were reviewed for the number, timing, and concordance of contents of the labeling change between countries/region.

Results

The number of labeling changes and median time from approval to the change (min, max) were 57 cases and 814 (90, 2454) days in Japan, 63 cases and 852 (161, 3051) days in the US, and 50 cases and 851 (157, 2699) days in the EU. Distribution of the revision date of the concordant labeling change in the three countries/region and distribution of differences in revision date between the two countries/region showed no trend of delayed labeling change in a specific country/region. Concordance rate of the labeling change was 36.1% (30/83) in US‐EU, 21.2% (21/99) in Japan‐US, and 23.0% (20/87) in Japan‐EU (Fisher's exact test, p = 0.0313 [Japan‐US vs. US‐EU], p = 0.066 [Japan‐EU vs. US‐EU]).

Conclusions

There was no trend of fewer or later labeling changes in Japan compared to those in the US/EU. While the concordance rate in US‐EU was low, that in Japan‐US and Japan‐EU were even lower. Further investigation is needed to understand the reasons for these differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalPharmacovigilanceUnited StatesHumansEuropean UnionJapan

Stichwörter der Autor:innen

EMAFDAPMDAadverse drug reactionlabelingpharmacovigilancesafety-related regulatory action

Autor:innen und Institutionen

  • Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Japan.

ORCID-Profile: Koichi Fukuda

Zitieren

APA

Fukuda, K., & Narukawa, M. (2023). Decision and timing of safety‐related labeling changes for new drugs in Japan: Comparison with the United States and the European Union. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5664

Vancouver

Fukuda K, Narukawa M. Decision and timing of safety‐related labeling changes for new drugs in Japan: Comparison with the United States and the European Union. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5664

BibTeX
@article{Fukuda2023,
  author = {Fukuda, Koichi and Narukawa, Mamoru},
  title = {Decision and timing of safety‐related labeling changes for new drugs in Japan: Comparison with the United States and the European Union},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2023},
  doi = {10.1002/pds.5664}
}
Kostenlos starten →